Kevin Feeley, an insider at GeneDx Holdings Corp (WGS), executed a sale of 8,884 shares on December 15, 2025, at a price of $149.20 per share, resulting in a total transaction value of $1.33 million. Following this transaction, Feeley retains 8,884 shares of the company.
GeneDx Holdings operates as a health intelligence company focused on genomic testing, particularly in pediatric and rare disease diagnostics. The firm, headquartered in Stamford, Connecticut, went public on September 4, 2020, and currently employs 1,000 full-time staff. The company’s offerings include various exome and genome sequencing tests aimed at translating complex genomic data into actionable clinical insights.
The sale by Feeley raises questions about insider sentiment, although such transactions can stem from a variety of personal financial needs, including diversification and tax planning. While significant insider selling may attract investor attention, it does not inherently signal negative outlooks on the company.
Insider trades are reported to the SEC, contributing to the transparency of executive actions. This particular transaction serves as one data point for investors, who should consider broader trends in insider activity alongside fundamental and technical analyses. Evaluating patterns of transactions across multiple insiders can provide a more comprehensive understanding of sentiment within the company.
As of November 18, 2025, GeneDx Holdings boasts a market capitalization of $4.0 billion and a P/E ratio of 1,922.81, with upcoming earnings estimates suggesting an EPS of $0.04 and revenue of $128.7 million for July 27, 2026.